19/05/2022
HemoHIM, a herbal preparation, alleviates airway inflammation
caused by cigarette smoke and lipopolysaccharide
Na-Rae Shin1, #, Sung-Ho Kim1, #, Je-Won Ko1
, Sung-Hyeuk Park1
, In-Chul Lee2,
Jung-Min Ryu1
, Jong-Choon Kim1
, In-Sik Shin1,*
1
College of Veterinary Medicine (BK21 Plus Project Team), Chonnam National University, Gwangju, Korea
2
Natural Product Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Korea
HemoHIM, herbal preparation has designed for immune system recovery. We investigated the antiinflammatory effect of HemoHIM on cigarette smoke (CS) and lipopolysaccharide (LPS) induced chronic
obstructive pulmonary disease (COPD) mouse model. To induce COPD, C57BL/6 mice were exposed to
CS for 1 h per day (eight ci******es per day) for 4 weeks and intranasally received LPS on day 26.
HemoHIM was administrated to mice at a dose of 50 or 100 mg/kg 1h before CS exposure. HemoHIM
reduced the inflammatory cell count and levels of tumor necrosis factor receptor (TNF)-α, interleukin (IL)-
6 and IL-1β in the broncho-alveolar lavage fluid (BALF) induced by CS+LPS exposure. HemoHIM
decreased the inflammatory cell infiltration in the airway and inhibited the expression of iNOS and MMP-
9 and phosphorylation of Erk in lung tissue exposed to CS+LPS. In summary, our results indicate that
HemoHIM inhibited a reduction in the lung inflammatory response on CS and LPS induced lung
inflammation via the Erk pathway. Therefore, we suggest that HemoHIM has the potential to treat
pulmonary inflammatory disease such as COPD.
For price, availability and details contact us.
